Szutowicz Ewa, Dziadziuszko Rafał
Department of Oncology and Radiotherapy, Medical University of Gdansk, Gdansk, Poland.
Folia Histochem Cytobiol. 2010 Jan 1;48(1):7-11. doi: 10.2478/v10042-010-0014-2.
Quantitative immunohistochemistry remains an important tool in translational lung cancer research with hopes to improve patient outcomes and avoid unnecessary therapies. Present review is aimed to summarize the use of immunohistochemical markers for improved prognostic information and prediction of treatment benefit. Several of these markers are currently explored in phase II-III clinical studies to individualize the treatment of lung cancer.
定量免疫组织化学仍然是转化肺癌研究中的一项重要工具，有望改善患者预后并避免不必要的治疗。本综述旨在总结免疫组化标志物在改善预后信息及预测治疗获益方面的应用。目前，其中一些标志物正在II-III期临床研究中进行探索，以实现肺癌治疗的个体化。
